Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Absorption Profiles of Three Polyphenol Preparations With and Without Pollen Shell Covering

Investigation Into Polyphenol Absorption Profiles

This study consists of two parts. The first part of the study looked at the absorption of three different polyphenol preparations into the blood, the variability of their absorption and whether their absorption could be enhanced by mixing with pollen shells. For this purpose 12 healthy volunteers were recruited. All participants received all the 3 supplements with and without mixing with pollen shells so they had a total of 3 tests. For each test six blood samples were taken over an 8 hour period. Urine samples were also collected.

Oligopin was selected from the first study. The second part of study aims to look at the effects of Oligopin on endothelial function by assessing vascular tone and function in healthy volunteers using a non-invasive, direct measurement of vasodilatory capacity (EndoPAT). Nitrate and nitrite measurements, as well as blood pressure measurements, will also be recorded to provide a clear clinical assessment of the effects of this preparation (if any) upon vascular function. The effects of Oligopin will be compared to a placebo (methylcellulose-filled capsules) to allow a robust assessment of any clinical effects. A total of 24 healthy volunteers will be recruited for this study.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

This study consists of two parts. The first part of the study looked at the absorption of three different polyphenol preparations into the blood, the variability of their absorption and whether their absorption could be enhanced by mixing with pollen shells (pollen shells have been shown to enhance lipid molecule absorption). For this purpose 12 healthy volunteers were recruited. All participants received all the 3 supplements with and without mixing with pollen shells so they had a total of 3 tests. For each test six blood samples were taken over an 8 hour period. Urine samples were also collected.

Oligopin was selected from the first study. The second part of study aims to look at the effects of Oligopin on endothelial function by assessing vascular tone and function in healthy volunteers using a non-invasive, direct measurement of vasodilatory capacity (EndoPAT). Nitrate and nitrite measurements, as well as blood pressure measurements, will also be recorded to provide a clear clinical assessment of the effects of this preparation (if any) upon vascular function. The effects of Oligopin will be compared to a placebo (methylcellulose-filled capsules) to allow a robust assessment of any clinical effects. A total of 24 healthy volunteers will be recruited for this study.

Studietype

Intervensjonell

Registrering (Faktiske)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • East Yorkshire
      • Hull, East Yorkshire, Storbritannia, HU3 2RW
        • Michael White Centre for Diabetes and Endocrinology

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

14 år til 61 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or Female subjects between the age of 18-65 who can speak and understand English
  2. No concomitant medication including herbal medicines and food supplements
  3. No concomitant disease processes
  4. Body Mass Index 21- 29kg/m2
  5. Systolic blood pressure ≤150 mm Hg and diastolic pressure <90 mm Hg
  6. Subjects who have given informed consent

Exclusion Criteria:

  1. Patients not wishing to allow disclosure to their GPs.
  2. Concomitant medication including herbal medicines and food supplements
  3. Concomitant disease processes
  4. History of drug/alcohol abuse or Alcohol intake within 24 hours of dosing visit (visits 2-4)
  5. Body Mass Index <21 and > 29kg/m2
  6. Systolic blood pressure >150 mm Hg and or a diastolic pressure>90 mm Hg
  7. Unable to tolerate polyphenol products or adhere to low polyphenol diet
  8. Vegetarian
  9. Subjects not willing or able to fast until 12 noon (a total of 14 hours).
  10. Pregnant females or planning to conceive in the next 3 months.
  11. Participation in any other study currently or in the last three months.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Polyphenol
Polyphenol preparations
Polyphenol

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Area Under the Absorption Curve for each polyphenol preparation
Tidsramme: 8 hours
Blood samples will be withdrawn 6 times over an 8 hour period: baseline, then 30 minutes, 1 hour, 2 hours, 4 hours and 8 hours after ingestion of each polyphenol supplement (total 3 supplements)
8 hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Thozhukat Sathyapalan, MBBS FRCP MD, University of Hull

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. april 2014

Primær fullføring (Faktiske)

1. mai 2015

Studiet fullført (Faktiske)

1. mai 2015

Datoer for studieregistrering

Først innsendt

15. april 2014

Først innsendt som oppfylte QC-kriteriene

15. april 2014

Først lagt ut (Anslag)

17. april 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. juli 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. juli 2019

Sist bekreftet

1. juli 2019

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • Protocol Version 2

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere